Lantus Loss Drags Down Sanofi's Diabetes Franchise
This article was originally published in Scrip
A nearly 20% drop in US sales of Sanofi's top-seller Lantus was largely to blame for a 6.6% fall in its diabetes franchise sales in the third quarter, leading the French pharma to lower its forecasts for its leading therapy segment.
You may also be interested in...
During third-quarter earnings report, Brandicourt said he remains confident about Sanofi's prospects in oncology despite losing the takeover fight for Medivation, although he didn't rule out another mid-sized bolt-on attempt if the opportunity arose.
Sanofi is putting more pressure on Medivation to accept its $9.3bn acquisition offer by proposing to replace the biotechnology company's and Xtandi developer's entire board of directors.
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.